Skip to content
Javascript must be enabled for the correct page display
About
Our Company
Executive Team
Board of Directors
Programs
Pipeline
Scientific Publications
Clinical Trials
Expanded Access Policy
Investors
Overview
News & Events
Corporate Governance
Financial Information
Stock Information
IR Resources
Careers
Join Our Team
Job Opportunities
Contact Us
Open mobile menu
Programs
Scientific Presentations
09.09.24 | WCLC | Presentation
FURTHER (FURMO-002): A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naïve, Advanced NSCLC with EGFR PACC Mutations
04.09.24 | AACR | Poster
FURVENT: Global, Phase 3 Trial Testing Furmonertinib versus Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR Exon 20 Insertion Mutations
04.08.24 | AACR | Poster
Furmonertinib is a highly brain-penetrant EGFR inhibitor broadly active against uncommon EGFR mutations, including PACC and exon 20 insertions
04.08.24 | AACR | Poster
FURTHER (FURMO-002): Global Study to Evaluate Furmonertinib in Patients with EGFR Mutant NSCLC Including Uncommon EGFR Mutations
09.10.23 | WCLC | Presentation
FAVOUR: A phase 1b study of furmonertinib, an oral. Brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR Exon 20 insertions.
09.09.22 | NACLC | Poster
Furmonertinib is an oral, irreversible, highly brain-penetrant Pan EGFR Mutant Inhibitor with activity against classical and atypical EGFR Mutations.
03.08.22 | ELCC | Presentation
FURLONG: Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase III study.
09.16.21 | ESMO | Poster
Preclinical and Preliminary Clinical Investigations of Furmonertinib in NSCLC with EGFR exon 20 insertions (20ins).